ArticleJournal of general internal medicine2009
Prescribers and pharmaceutical representatives: why are we still meeting?
Article in Journal of general internal medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review.Annals of internal medicine · 2021Pooled it
- Pooled it
- Interactions between non-physician clinicians and industry: a systematic review.PLoS medicine · 2013Pooled it
- Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.PLoS medicine · 2010Pooled it
- The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.Journal of studies on alcohol and drugs · 2014Trial
- Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.Journal of studies on alcohol and drugs · 2014Trial
- A randomized trial evaluating 2 approaches for promoting pharmacy-based referrals to the tobacco quitline: methods and baseline findings.Research in social & administrative pharmacy : RSAPTrial
- Industry payments to US neurologists related to multiple sclerosis drugs and prescribing (2015-2019): a retrospective cohort study.BMJ open · 2025Observational
- "I never thought of it as payment": Qualitative evaluation of workshops with advanced practice registered nurses on pharmaceutical industry payment reporting.Journal of the American Association of Nurse Practitioners · 2025Article
- Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.BMJ (Clinical research ed.) · 2023Article
- Behavioral Components and Context of Antimicrobial Prescription in a Tertiary Hospital in Portugal.Antibiotics (Basel, Switzerland) · 2023Article
- The Role of Physician Networks and Receipt of Opioid-Related Payments.Journal of general internal medicine · 2023Article
- Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?Journal of health politics, policy and law · 2022Article
- Pharmaceutical Sales Representatives in the United States and China: The Need for Professional Public Space.Health care analysis : HCA : journal of health philosophy and policy · 2022Article
- Article
- GPs' perceptions of their relationship with the pharmaceutical industry: a qualitative study.BJGP open · 2021Article
- Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.Health services research · 2019Article
- The intersections of industry with the health research enterprise.Health research policy and systems · 2019Article
- Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses.JAMA network open · 2019Article
- The social biography of antibiotic use in smallholder dairy farms in India.Antimicrobial resistance and infection control · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextResearch suggests that pharmaceutical marketing influences prescribing and may cause cognitive dissonance for prescribers. This work has primarily been with physicians and physician-trainees. Questions remain regarding why prescribers continue to meet with pharmaceutical representatives (PRs).
objectiveTo describe the reasons that prescribers from various health professions continue to interact with PRs despite growing evidence of the influence of these interactions. DESIGN, SETTING, AND
participantsMulti-disciplinary focus groups with 61 participants held in practice settings and at society meetings.
resultsMost prescribers participating in our focus groups believe that overall PR interactions are beneficial to patient care and practice health. They either trust the information from PRs or feel that they are equipped to evaluate it independently. Despite acknowledgement of study findings to the contrary, prescribers state that they are able to effectively manage PR interactions such that their own prescribing is not adversely impacted. Prescribers describe few specific strategies or policies for these interactions, and report that policies are not consistently implemented with all members of a clinic or institution. Some prescribers perceive an inherent contradiction between academic centers and national societies receiving money from pharmaceutical companies, and then recommending restriction at the level of the individual prescriber. Prescribers with different training backgrounds present a few novel reasons for these meetings.
conclusionsDespite evidence that PR detailing influences prescribing, providers from several health professions continue to believe that PR interactions improve patient care, and that they can adequately evaluate and filter information presented to them by PRs. Focus group comments suggest that cultural change is necessary to break the norms that exist in many settings. Applying policies consistently, considering non-physician members of the healthcare team, working with trainees, restructuring the current primary care model and offering convenient, individualized, non-biased educational options may aid success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.